Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 3.5% – Still a Buy?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s share price traded up 3.5% on Friday . The stock traded as high as $0.28 and last traded at $0.26. 29,962,066 shares traded hands during mid-day trading, a decline of 57% from the average session volume of 68,989,281 shares. The stock had previously closed at $0.26.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Thursday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Trading Up 2.7 %

The firm has a market cap of $49.13 million, a P/E ratio of 0.00 and a beta of 2.02. The company has a 50 day moving average of $0.25 and a 200 day moving average of $0.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.